Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Divan"


7 mentions found


Stocks that have missed out on this year's market rally could be solid contenders for a rebound, according to Goldman Sachs. Heading into the second quarter, Goldman searched for buy-rated names in its coverage universe that could win big going forward. Goldman screened for "compounders," which offer investors high financial returns, free cash flow generation, margin expansion and sales growth. Most analysts covering the stock currently have a buy rating assigned to the name, with about 39% upside to the consensus price target, per LSEG. Pfizer stock has slipped 9% this year.
Persons: Goldman Sachs, Goldman, Dan Levy, Levy, Guggenheim, Vamil Divan, Lamb Weston, Jefferies, Rob Dickerson Organizations: Barclays, Pfizer Locations: U.S
In early 2008, I was working on the New York Philharmonic’s concert in Pyongyang, a project conceived to enhance the atmosphere of the six-party talks on the denuclearization of North Korea. At the time, observers and even many of the musicians themselves questioned whether any potential good would come of the effort. I think the end of the North Korea story is not yet written. Mr. Barenboim formed the orchestra with his longtime friend and intellectual partner, the Palestinian-American scholar Edward Said, who died in 2003. I arranged the first U.S. visit of the orchestra, which brings young Israeli, Palestinian and other Arab musicians together to make music.
Persons: Madeleine Albright’s, Dvorak, Gershwin, reminisced, Leonard Bernstein, Daniel Barenboim, Barenboim, Edward Said Organizations: York, Chicago Symphony Orchestra, Divan, Mr Locations: Pyongyang, North Korea, North Koreans, Soviet Union, Korea, Buenos Aires, London, United States, West, Palestinian, U.S
The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. J&J raised its annual profit forecast, helped by strong sales from its pharmaceutical business, and shares of the U.S. healthcare conglomerate were off about 1%. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, up from its previous view of $10.00 to $10.10. Sales at J&J's medical device unit came in at $7.46 billion, shy of Wall Street estimates of $7.58 billion. J&J finalized the biggest shake-up in its 137-year history in August with the spinoff, but retained a 9.5% stake in its iconic consumer health business.
Persons: Johnson, Yves Herman, J, Vamil Divan, Joseph Wolk, Ozempic, Wolk, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta, Bill Berkrot Organizations: Johnson, REUTERS, Guggenheim Partners, Vamil, Reuters Graphics, J, Thomson, &' $, & $, & $ Locations: Brussels, Diegem, Belgium, Bengaluru, New York
Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022. J&J is forecasting $57 billion in pharmaceutical sales by 2025 after reducing its previous view of $60 billion in April, citing currency dynamics that hurt its pharmaceutical business in 2022. That would add around $4.6 billion to average estimates for pharmaceutical sales, as long as no biosimilars enter the market before 2025. Amgen said last month the confidential settlement it signed with J&J will allow it to sell its Stelara biosimilar no later than Jan. 1, 2025. “If no Stelara biosimilars enter in 2024, I think growth should continue at around 4% in 2023 and 2024,” Huynh said.
Persons: Johnson, Amgen, , Vamil, Trung Huynh, ” Huynh, Teva, biosimilar, Divan, Alvotech, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Amgen Inc, Analysts, Stelara, Reuters Graphics Reuters, Reuters, New, J, Credit Suisse, Food and Drug Administration, Alvotech’s, Thomson Locations: New Brunswick , New Jersey, Alvotech’s Reykjavik
Johnson & Johnson on Wednesday said it's ducking out of the RSV vaccine race, weeks after competitors Pfizer and GSK inched closer to launching the world's first shot against the deadly virus. J&J will stop working on its investigational RSV adult vaccine program and discontinue a pivotal phase three trial testing the shot, the company announced in a press release. Since then, the race to create the world's first RSV vaccine has garnered more attention than ever. A phase two trial on the company's RSV shot found it provided 80% protection against severe RSV infections. Drugmaker Moderna also has its own potential RSV shot, which performed well in clinical trials.
Inundațiile puternice din 2010 au şters aproape complet de pe hartă satul Cotul Morii, din raionul Hîncești. Așa arată satul vechi Cotul Morii din raionul Hîncești, care în 2010 a fost spălat la propriu de inundații puternice. Maria Ganganu are 70 de ani şi își amintește cu durere despre nenorocirea de acum 11 ani.”Apa până la ferestre a fost în casă. Eu am tot timpul ocupație.”Satul Cotul Morii a fost reconstruit pe un deal, unde au fost ridicate 700 de case noi. Aici era aproape, doi pași până la Prut.”În comuna Cotul Morii locuiesc peste 2200 de oameni.
Persons: Stihia, Maria Ganganu, Maria Ganganu.Femeia, Scurcan Locations: Hîncești, Prut
Negustorul de sclavi (5). Marele ban
  + stars: | 2020-05-27 | by ( Doina Ruşti | ) adevarul.ro   time to read: +4 min
Pe vremea când era banul Craiovei, Gheorma mai face şi fapte bune. Din acelaşi document aflăm, că domnitorul, acest Cârn, aproape anonim printre domni, a cerut să vadă cărţile întocmite şi semnate de Ghiorma - marele ban. Acesta vinde o casă din Capitală, cu grădină şi vie, invocând faptul că a fost dorinţa tatălui său, marele ban. Aproape că nu e document în care acest Alexandru să nu-şi evoce cu evlavie tatăl. Prin urmare: Cârnu n-a avut încredere în el, în schimb, în familie, Gheorma a fost venerat.
Persons: Radu, Oprea, Martin, Cleman, Radul, Neagoe, dracul, Duca, Stoica, Vâlsan, Nica, Stan, Costandin, Leu, Constantin, Gheorma, Alexandru, Brâncoveanu, stolnicul Constantin Cantacuzino Organizations: Divan Locations: japca, Romanaţi, Bucureşti, Dobreni, Bad Arolsen, Capitală, Italia
Total: 7